Neomend's vascular closure study gains FDA nod:
This article was originally published in Clinica
Executive Summary
Neomend is to begin a US trial to evaluate its arterial closure device in treating patients who have received punctures to the femoral artery in the leg. The device is intended to achieve haemostasis of arterial punctures in patients who have undergone diagnostic or interventional procedures. It can be used safely in a variety of patients, including those requiring immediate or chronic repunctures, closure of either antegrade or retrograde punctures and those taking GP IIb/IIIa inhibitors, said the Sunnyvale, California firm.